Cerevel Therapeutics Holdings, Inc. financial data

Industry
Pharmaceutical Preparations
Location
222 Jacobs Street, Suite 200, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
ARYA Sciences Acquisition Corp II (to 10/26/2020)
Latest financial report
10-Q - Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.03K % -20.8%
Debt-to-equity 120 % +47.4%
Return On Equity -98.9 % -28.2%
Return On Assets -45.1 % -5.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 182M shares +16%
Common Stock, Shares, Outstanding 182M shares +16%
Entity Public Float 2.2B USD +39.6%
Common Stock, Value, Issued 18K USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 182M shares +15.9%
Weighted Average Number of Shares Outstanding, Diluted 182M shares +15.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 363M USD +19.6%
General and Administrative Expense 127M USD +39.4%
Operating Income (Loss) -490M USD -24.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -460M USD -18.8%
Income Tax Expense (Benefit) 556K USD +62.4%
Net Income (Loss) Attributable to Parent -460M USD -18.8%
Earnings Per Share, Basic -2.73 USD/shares -7.91%
Earnings Per Share, Diluted -2.73 USD/shares -7.91%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 320M USD +108%
Other Assets, Current 77K USD -94.4%
Assets, Current 860M USD +2.24%
Property, Plant and Equipment, Net 24.9M USD -7.69%
Operating Lease, Right-of-Use Asset 19.7M USD -8.24%
Other Assets, Noncurrent 2.62M USD -18.4%
Assets 1.13B USD +21.2%
Accounts Payable, Current 10.8M USD +48.2%
Employee-related Liabilities, Current 6.94M USD +8.89%
Liabilities, Current 84.1M USD +33.6%
Operating Lease, Liability, Noncurrent 26.9M USD -11.6%
Other Liabilities, Noncurrent 2K USD -99.2%
Liabilities 563M USD +12.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.09M USD -130%
Retained Earnings (Accumulated Deficit) -1.53B USD -43%
Stockholders' Equity Attributable to Parent 564M USD +30.7%
Liabilities and Equity 1.13B USD +21.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -120M USD -26.1%
Net Cash Provided by (Used in) Financing Activities 4.48M USD +212%
Net Cash Provided by (Used in) Investing Activities 19.2M USD -82.7%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 182M shares +16%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 322M USD +107%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.31M USD +0.56%
Deferred Tax Assets, Valuation Allowance 377M USD +53.6%
Deferred Tax Assets, Gross 388M USD +51.2%
Operating Lease, Liability 31.2M USD -8.5%
Payments to Acquire Property, Plant, and Equipment 271K USD -19.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -465M USD -21.6%
Lessee, Operating Lease, Liability, to be Paid 41.8M USD -12.7%
Operating Lease, Liability, Current 3.52M USD +16.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.46M USD +2.67%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.29M USD +3.17%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.6M USD -23.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.66M USD +3.16%
Deferred Tax Assets, Operating Loss Carryforwards 146M USD +20.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.86M USD +3%
Additional Paid in Capital 2.1B USD +39.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.54M USD +16.7%
Deferred Tax Assets, Net of Valuation Allowance 11.5M USD -0.32%
Share-based Payment Arrangement, Expense 77.8M USD +81.6%
Interest Expense 10.6M USD +0.61%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%